Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma

Human Molecular Genetics

Volumn 20, Issue 20, 2011, Pages 3974-3985

  Burnichon, Nelly ^a,b,c   Vescovo, Laure ^d   Amar, Laurence ^a,b,c   Libé, Rossella ^c,e,f,g   de Reynies, Aurélien ^d   Venisse, Annabelle ^b   Jouanno, Elodie ^b   Laurendeau, Ingrid ^h   Parfait, Béatrice ^h,i   Bertherat, Jérôme ^c,e,f,g   Plouin, Pierre François ^a,b,c,g   Jeunemaitre, Xavier ^a,b,c   Favier, Judith ^a,c   Gimenez Roqueplo, Anne Paule ^a,b,c,g  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Programme Cartes d'Identite des Tumeurs   (France)

^e INSTITUT COCHIN   (France)

^f Institut Cochin ^*  (France)

^g INSTITUT NATIONAL DU CANCER   (France)

^h INSERM   (France)

ⁱ BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; TRANSCRIPTOME; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; INTEGRATIVE GENOMIC ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; SDHX GENE; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADRENAL GLAND NEOPLASMS; CHROMOSOME MAPPING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; PARAGANGLIOMA, EXTRA-ADRENAL; PHEOCHROMOCYTOMA;

EID: 80053139912     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr324     Document Type: Article

References (58)

1. Gimenez-Roqueplo, A.P., Burnichon, N., Amar, L., Favier, J., Jeunemaitre, X. and Plouin, P.F. (2008) Recent advances in the genetics of phaeochromocytoma and functional paraganglioma. Clin. Exp. Pharmacol. Physiol., 35, 376-379.
2. Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A. et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol., 23, 8812-8818.
3. Neumann, H.P., Pawlu, C., Peczkowska, M., Bausch, B., McWhinney, S.R., Muresan, M., Buchta, M., Franke, G., Klisch, J., Bley, T.A. et al. (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA, 292, 943-951.
4. Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54.
5. Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851.
6. Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270.
7. Burnichon, N., Briere, J.J., Libe, R., Vescovo, L., Riviere, J., Tissier, F., Jouanno, E., Jeunemaitre, X., Benit, P., Tzagoloff, A. et al. (2010) SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet., 19, 3011-3020.
8. Hao, H.X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J.P., Kunst, H., Devilee, P., Cremers, C.W., Schiffman, J.D., Bentz, B.G. et al. (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 325, 1139-1142.
9. Qin, Y., Yao, L., King, E.E., Buddavarapu, K., Lenci, R.E., Chocron, E.S., Lechleiter, J.D., Sass, M., Aronin, N., Schiavi, F. et al. (2010) Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat. Genet., 42, 229-233.
10. Eisenhofer, G., Huynh, T.T., Pacak, K., Brouwers, F.M., Walther, M.M., Linehan, W.M., Munson, P.J., Mannelli, M., Goldstein, D.S. and Elkahloun, A.G. (2004) Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr. Relat. Cancer, 11, 897-911.
11. Dahia, P.L., Ross, K.N., Wright, M.E., Hayashida, C.Y., Santagata, S., Barontini, M., Kung, A.L., Sanso, G., Powers, J.F., Tischler, A.S. et al. (2005) A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet., 1, 72-80.
12. Lopez-Jimenez, E., Gomez-Lopez, G., Leandro-Garcia, L.J., Munoz, I., Schiavi, F., Montero-Conde, C., de Cubas, A.A., Ramires, R., Landa, I., Leskela, S. et al. (2010) Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol. Endocrinol., 24, 2382-2391.
13. Hensen, E.F., Goeman, J.J., Oosting, J., Van der Mey, A.G., Hogendoorn, P.C., Cremers, C.W., Devilee, P. and Cornelisse, C.J. (2009) Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis. BMC Med. Genomics, 2, 25.
14. Dahia, P.L., Hao, K., Rogus, J., Colin, C., Pujana, M.A., Ross, K., Magoffin, D., Aronin, N., Cascon, A., Hayashida, C.Y. et al. (2005) Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res., 65, 9651-9658.
15. Yao, L., Schiavi, F., Cascon, A., Qin, Y., Inglada-Perez, L., King, E.E., Toledo, R.A., Ercolino, T., Rapizzi, E., Ricketts, C.J. et al. (2010) Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA, 304, 2611-2619.
16. Favier, J., Briere, J.J., Burnichon, N., Riviere, J., Vescovo, L., Benit, P., Giscos-Douriez, I., De Reynies, A., Bertherat, J., Badoual, C. et al. (2009) The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE, 4, e7094.
17. Nordstrom-O'Brien, M., van der Luijt, R.B., van Rooijen, E., van den Ouweland, A.M., Majoor-Krakauer, D.F., Lolkema, M.P., van Brussel, A., Voest, E.E. and Giles, R.H. (2010) Genetic analysis of von Hippel-Lindau disease. Hum. Mutat., 31, 521-537.
18. Bayley, J.P., Devilee, P. and Taschner, P.E. (2005) The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med. Genet., 6, 39.
19. Desmet, F.O., Hamroun, D., Lalande, M., Collod-Beroud, G., Claustres, M. and Beroud, C. (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res., 37, e67.
20. van Nederveen, F.H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R.A., de Bruyn, E.M., Sleddens, H.F., Derkx, P., Riviere, J., Dannenberg, H. et al. (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol., 10, 764-771.
21. Gill, A.J., Benn, D.E., Chou, A., Clarkson, A., Muljono, A., Meyer-Rochow, G.Y., Richardson, A.L., Sidhu, S.B., Robinson, B.G. and Clifton-Bligh, R.J. (2010) Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum. Pathol., 41, 805-814.
22. Vortmeyer, A.O., Huang, S.C., Pack, S.D., Koch, C.A., Lubensky, I.A., Oldfield, E.H. and Zhuang, Z. (2002) Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene, 21, 1167-1170.
23. Janavicius, R., Adomaitis, R., Jankevicius, F. and Griskevicius, L. (2009) Extremely low risk of pheochromocytomas in complete VHL gene deletion cases. Hum. Mutat., 30, 1365-1366; author reply 1367.
24. Kim, W.Y. and Kaelin, W.G. (2004) Role of VHL gene mutation in human cancer. J. Clin. Oncol., 22, 4991-5004.
25. Garcia-Linares, C., Fernandez-Rodriguez, J., Terribas, E., Mercade, J., Pros, E., Benito, L., Benavente, Y., Capella, G., Ravella, A., Blanco, I. et al. (2011) Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: importance of copy neutral LOH. Hum. Mutat., 32, 78-90.
26. Stephens, K., Weaver, M., Leppig, K.A., Maruyama, K., Emanuel, P.D., Le Beau, M.M. and Shannon, K.M. (2006) Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood, 108, 1684-1689.
27. Hensen, E.F., Jordanova, E.S., van Minderhout, I.J., Hogendoorn, P.C., Taschner, P.E., van der Mey, A.G., Devilee, P. and Cornelisse, C.J. (2004) Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene, 23, 4076-4083.
28. Eisenhofer, G., Pacak, K., Huynh, T.T., Qin, N., Bratslavsky, G., Linehan, W.M., Mannelli, M., Friberg, P., Grebe, S.K., Timmers, H.J. et al. (2011) Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr. Relat. Cancer, 18, 97-111.
29. Eisenhofer, G., Lenders, J.W., Timmers, H., Mannelli, M., Grebe, S.K., Hofbauer, L.C., Bornstein, S.R., Tiebel, O., Adams, K., Bratslavsky, G. et al. (2011) Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin. Chem., 57, 411-420.
30. Pollard, P.J., El-Bahrawy, M., Poulsom, R., Elia, G., Killick, P., Kelly, G., Hunt, T., Jeffery, R., Seedhar, P., Barwell, J. et al. (2006) Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J. Clin. Endocrinol. Metab., 91, 4593-4598.
31. Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.P. et al. (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab., 92, 3822-3828.
32. Timmers, H.J., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K.T., Solis, D., Lenders, J.W. and Pacak, K. (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab., 92, 779-786.
33. Llano, E., Pendas, A.M., Freije, J.P., Nakano, A., Knauper, V., Murphy, G. and Lopez-Otin, C. (1999) Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res., 59, 2570-2576.
34. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E. and Seiki, M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 370, 61-65.
35. Lu, Y., Lemon, W., Liu, P.Y., Yi, Y., Morrison, C., Yang, P., Sun, Z., Szoke, J., Gerald, W.L., Watson, M. et al. (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med., 3, e467.
36. Ng, K.T., Lee, T.K., Cheng, Q., Wo, J.Y., Sun, C.K., Guo, D.Y., Lim, Z.X., Lo, C.M., Poon, R.T., Fan, S.T. et al. (2010) Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1. Int. J. Cancer, 127, 859-872.
37. Ragazzon, B., Libe, R., Gaujoux, S., Assie, G., Fratticci, A., Launay, P., Clauser, E., Bertagna, X., Tissier, F., de Reynies, A. et al. (2010) Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res., 70, 8276-8281.
38. Yang, H., Xiong, F., Wei, X., Yang, Y., McNutt, M.A. and Zhou, R. (2010) Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett., 294, 236-244.
39. Yin, M., Xu, Y., Lou, G., Hou, Y., Meng, F., Zhang, H., Li, C. and Zhou, R. (2011) LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int. J. Cancer, 129, 629-635.
40. Li, X., Zhang, Y., Cao, S., Chen, X., Lu, Y., Jin, H., Sun, S., Chen, B., Liu, J., Ding, J. et al. (2009) Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis. Int. J. Cancer, 124, 713-721.
41. Lu, B., Ma, Y., Wu, G., Tong, X., Guo, H., Liang, A., Cong, W., Liu, C., Wang, H., Wu, M. et al. (2008) Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma. Clin. Cancer Res., 14, 7405-7412.
42. Tong, X., Li, K., Luo, Z., Lu, B., Liu, X., Wang, T., Pang, M., Liang, B., Tan, M., Wu, M. et al. (2009) Decreased TIP30 expression promotes tumor metastasis in lung cancer. Am. J. Pathol., 174, 1931-1939.
43. Huynh, T.T., Pacak, K., Wong, D.L., Linehan, W.M., Goldstein, D.S., Elkahloun, A.G., Munson, P.J. and Eisenhofer, G. (2006) Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Ann. N. Y. Acad. Sci., 1073, 241-252.
44. Burnichon, N., Rohmer, V., Amar, L., Herman, P., Leboulleux, S., Darrouzet, V., Niccoli, P., Gaillard, D., Chabrier, G., Chabolle, F. et al. (2009) The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J. Clin. Endocrinol. Metab., 94, 2817-2827.
45. Mannelli, M., Castellano, M., Schiavi, F., Filetti, S., Giacche, M., Mori, L., Pignataro, V., Bernini, G., Giache, V., Bacca, A. et al. (2009) Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J. Clin. Endocrinol. Metab., 94, 1541-1547.
46. Dannenberg, H., De Krijger, R.R., van der Harst, E., Abbou, M., Ijzendoorn, Y., Komminoth, P. and Dinjens, W.N. (2003) Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int. J. Cancer, 105, 190-195.
47. Nakamura, E. and Kaelin, W.G. Jr. (2006) Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr. Pathol., 17, 97-106.
48. Souglakos, J., Philips, J., Wang, R., Marwah, S., Silver, M., Tzardi, M., Silver, J., Ogino, S., Hooshmand, S., Kwak, E. et al. (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer, 101, 465-472.
49. De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P. et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol., 11, 753-762.
50. Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Minotti, V., Colella, R., Giuffrida, D., Tofanetti, F.R., Siggillino, A., Flacco, A. et al. (2011) Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 6, 707-715.
51. Plouin, P.F. and Gimenez-Roqueplo, A.P. (2006) Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. Best. Pract. Res. Clin. Endocrinol. Metab., 20, 421-434.
52. Burnichon, N., Lepoutre-Lussey, C., Laffaire, J., Gadessaud, N., Molinie, V., Hernigou, A., Plouin, P.F., Jeunemaitre, X., Favier, J. and Gimenez-Roqueplo, A.P. (2011) A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. Eur. J. Endocrinol., 164, 141-145.
53. Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J. et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol., 5, R80.
54. Yang, Y.H., Dudoit, S., Luu, P., Lin, D.M., Peng, V., Ngai, J. and Speed, T.P. (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res., 30, e15.
55. Hupe, P., Stransky, N., Thiery, J.P., Radvanyi, F. and Barillot, E. (2004) Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics, 20, 3413-3422.
56. Goeman, J.J., van de Geer, S.A., de Kort, F. and van Houwelingen, H.C. (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics, 20, 93-99.
57. Pasmant, E., Sabbagh, A., Masliah-Planchon, J., Haddad, V., Hamel, M.J., Laurendeau, I., Soulier, J., Parfait, B., Wolkenstein, P., Bieche, I. et al. (2009) Detection and characterization of NF1 microdeletions by custom high resolution array CGH. J. Mol. Diagn., 11, 524-529.
58. Favier, J., Kempf, H., Corvol, P. and Gasc, J.M. (1999) Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase. FEBS Lett., 462, 19-24.